BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Synbiotics (SBIO) Announces Distribution Agreement Wth Meridian Bioscience, Inc. (VIVO)


10/19/2005 5:13:03 PM

SAN DIEGO--(BUSINESS WIRE)--March 16, 2005--Synbiotics Corporation (Pink Sheets:SBIO) announced today that it has entered into a Distribution Agreement with Viral Antigens, Inc. (VAI), a wholly-owned subsidiary of Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) for the distribution of VAI's veterinary products through Synbiotics' global sales, marketing and distribution channels. Synbiotics currently develops, manufactures, and markets veterinary diagnostic products for the global animal health market and is seeking to broaden its product portfolio. Synbiotics will immediately begin marketing the Pseudorabies Virus Antibody test kit and the Autolex(R) Anti-PRV Screen globally. VAI will continue to supply PRV test kits directly to Japan. Pseudorabies Virus (PRV) is a contagious swine disease that causes reproductive problems, including abortion, stillbirths and even occasional death losses in breeding and finishing hogs. PRV has been one of the most costly of all swine diseases to the nation's pork producers. At its peak in the 1990's, the cost to pork producers alone was estimated to be $30 million annually represented in vaccination, testing, and animal loss costs. Over the past decade, a national control and eradication program for PRV was implemented to eliminate the presence of PRV in the swine population. Today, tight biosecurity, vaccination, testing, and good disease management practices are utilized to control the impact of PRV.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES